文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

作者信息

Hegde Upendra P, Mukherji Bijay, Grant-Kels Jane M

机构信息

University of CT Health Center Cutaneous Oncology & Melanoma Center, 21 South Road, Farmington, CT 06030, USA.

Neag Cancer Center at UCONN Health, Farmington, CT 06032, USA.

出版信息

Melanoma Manag. 2016 Mar;3(1):9-12. doi: 10.2217/mmt.15.39. Epub 2016 Feb 17.

DOI:10.2217/mmt.15.39
PMID:30190868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6094635/
Abstract
摘要

相似文献

[1]
Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Melanoma Manag. 2016-3

[2]
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 T cell trafficking.

Proc Natl Acad Sci U S A. 2018-1-31

[3]
Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Exp Gerontol. 2018-1-8

[4]
Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?

Cancers (Basel). 2022-3-28

[5]
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

Eur J Cancer. 2021-5

[6]
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.

Melanoma Res. 2018-8

[7]
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study.

Postepy Dermatol Alergol. 2019-10

[8]
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.

J Dtsch Dermatol Ges. 2020-6

[9]
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Front Immunol. 2020

[10]
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.

Proc Natl Acad Sci U S A. 2019-10-21

引用本文的文献

[1]
Age-related transcriptome changes in melanoma patients with tumor-positive sentinel lymph nodes.

Aging (Albany NY). 2020-12-29

[2]
Welcome to the fourth volume of and a look back at 2016.

Melanoma Manag. 2017-3

本文引用的文献

[1]
Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

Hum Immunol. 2013-2-4

[2]
Management of immune-related adverse events and kinetics of response with ipilimumab.

J Clin Oncol. 2012-5-21

[3]
Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

Expert Rev Pharmacoecon Outcomes Res. 2011-4

[4]
Improved survival with ipilimumab in patients with metastatic melanoma.

N Engl J Med. 2010-6-5

[5]
Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.

Arch Dermatol. 2010-3

[6]
Final version of 2009 AJCC melanoma staging and classification.

J Clin Oncol. 2009-11-16

[7]
Melanoma in the elderly patient: relevance of the aging immune system.

Clin Dermatol. 2009

[8]
Human T cell responses against melanoma.

Annu Rev Immunol. 2006

[9]
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.

Cancer Biother Radiopharm. 2005-2

[10]
Cancer immunotherapy: moving beyond current vaccines.

Nat Med. 2004-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索